Polycystic ovary syndrome (PCOS) is the commonest cause of anovulatory infertility and accounts for approximately 15 -20% of all cases of infertility (1 ) .
Clinical features of PCOS cover a wide spectrum, including hirsutism, oligomenorrhoea or amenorrhoea, infertility and obesity (2) . Hormonal abnorm¬ alities in PCOS patients include elevated androgen and oestrone levels, elevated basal and GnRH-stimulated LH levels, elevated LH/FSH ratio, hyperinsulinaemia and insulin resistance (3) (4) (5) . The pathogenesis of this disorder has not been established definitively and it is the subject of on-going review (3, 6, 7) . Available treatment is non-specific and frequently unsatisfac¬ tory (3, 6, 8, 9) . Polycystic ovary syndrome may be associated with several abnormalities occurring sin¬ gularly or together, including disorders of the ovaries (10) , the adrenals (11, 12) , the hypothalamicpituitary axis (13) and hyperinsulinaemia with insulin resistance (14, 15) . However, whether these abnormalities are pathogenic in the development of PCOS or occur as a consequence of the disorder is unknown. In some instances clearly distinct abnorm¬ alities, e.g. congenital adrenal hyperplasia (16), Cushing's syndrome (17) (25) . Plasma levels of testosterone, androstenedione, oestrone, oestradiol and 17-hydroxyprogesterone were measured by specific radioimmunoassays similar to that described previously for aldosterone (26) . These radio¬ immunoassays were performed following extraction into diethyl ether and, in the case of androgens and oestrogens, after isolation of the steroids by chromatography over celite columns (27) . Plasma Using the hirsutism score system devised by Ferriman and Gallwey (32) 
